Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Episurf Medical ABLTS:0QUT -2.42% EV-to-FCF is -11.03 as of Jul. 24, 2026. The stock has 7 warning signs investors should review. Among 414 Medical Devices & Instruments companies, Episurf Medical AB ranks worse than 241545.65% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Episurf Medical AB's Enterprise Value is kr379.53 Mil.
Episurf Medical AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr-34.40 Mil. Therefore, Episurf Medical AB's EV-to-FCF for today is -11.03.
The historical rank and industry rank for Episurf Medical AB's EV-to-FCF or its related term are showing as below:
LTS:0QUT'
s EV-to-FCF Range Over the Past 10 Years
Min: -14.69 Med: -1.75 Max: 0.39
Current: -11.4
During the past 13 years, the highest EV-to-FCF of Episurf Medical AB was 0.39. The lowest was -14.69. And the median was -1.75.
LTS:0QUT's EV-to-FCF is ranked worse than 100% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 22.995
vs LTS:0QUT: -11.40
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Episurf Medical AB (LTS:0QUT) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Episurf Medical AB's PE Ratio (TTM) for today is calculated as:
Episurf Medical AB's share price for today is kr0.0565.
Episurf Medical AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.050.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Episurf Medical AB EV-to-FCF Related Terms
Episurf Medical AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Episurf Medical AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Episurf Medical AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Episurf Medical AB EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Episurf Medical AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Episurf Medical AB's EV-to-FCF falls into.
Episurf Medical AB's current Enterprise Value is kr379.53 Mil.
Episurf Medical AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-34.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Episurf Medical AB (LTS:0QUT) has a EV-to-FCF of -11.03 as of Jul. 24, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Episurf Medical AB and its competitors. According to the industry distribution chart, Episurf Medical AB ranks #999999 out of 414 companies in the Medical Devices & Instruments industry.
Is Episurf Medical AB's EV-to-FCF too high?
Episurf Medical AB's current EV-to-FCF is -11.03. Based on the distribution chart, Episurf Medical AB ranks #999999 out of 414 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Episurf Medical AB's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Episurf Medical AB ranks #999999 out of 414 companies for EV-to-FCF. This places Episurf Medical AB in the lower half of its industry. The industry median EV-to-FCF is 23.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.00, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Episurf Medical AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Episurf Medical AB's current EV-to-FCF is -11.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Episurf Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Episurf Medical AB (LTS:0QUT) is currently considered Modestly Overvalued. The stock's GF Value™ is kr0.05, compared to a current price of kr0.06 — trading 13% above its estimated fair value. The current EV-to-FCF is -11.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Episurf Medical AB (LTS:0QUT), the current EV-to-FCF is -11.03 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Episurf Medical AB is a medical device company. The company develops, manufactures, and commercializes solutions for the repair of the local cartilage damage in human joints. Its first patient-specific product portfolio, the knee portfolio, consists of the existing products Episealer Condyle Solo and Episealer Trochlea Solo, Episealer Femoral Twin, Epiguide MOS, and Epioscopy. Episealer Patellofemoral System for the treatment of osteoarthritis limited to thepatellofemoral part of the knee joint. The company is forming a new strategic business segment through the acquisition of real estate assets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QUT has been successfully added to your 
